ALZpath is looking to broaden access to its pTau217 antibody. Credit: Tatiana from Pixabay.

ALZpath has entered a licensing agreement with Roche for the use of the pTau217 antibody in blood tests to diagnose Alzheimer’s disease.

The agreement allows Roche to utilise ALZpath’s antibody for the development and commercialisation of a blood test for Alzheimer’s.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Planned to be made available on the Roche Elecsys platform, the test aims to offer a less invasive and more cost-effective diagnostic option compared to current methods.

The Roche pTau217 test has recently obtained the US Food and Drug Administration’s (FDA) breakthrough device designation.

The collaboration between Roche and pharmaceutical company Eli Lilly will facilitate the commercialisation of this blood test.

pTau217 is a biomarker intended for the detection and monitoring of Alzheimer’s disease progression in blood.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Blood assays employing the ALZpath pTau217 antibody have demonstrated comparable accuracy to PET imaging or CSF testing.

However, these blood assays offer the benefits of being less invasive and more affordable.

ALZpath is looking to broaden access to its pTau217 antibody, enabling its application in various clinical and research environments.

The company is also seeking partnerships with diagnostic companies to distribute its technology to laboratories around the world.

ALZpath CEO Venkat Shastri said: “The field has been waiting for highly accurate and reliable plasma pTau217 assays on widely available, fully automated commercial testing platforms, and we are thrilled that ALZpath’s proprietary antibody has been selected by Roche to play that vital role on the Elecsys platform.

“ALZpath’s expertise in developing novel antibodies for precisely detecting the presence and progression of Alzheimer’s disease in blood, combined with Roche’s leading in-vitro diagnostics instrument base, represents a key step toward global availability of testing as treatments emerge.”

Last month, Roche obtained the FDA’s breakthrough device designation for its Tina-quant lipoprotein Lp(a) RxDx assay, a diagnostic tool for cardiovascular disease risk.